Rowan University

Rowan Digital Works

Rowan-Virtua Research Day

28th Annual Research Day

May 2nd, 12:00 AM

The Effects of Psychedelic Microdosing on Mental Health: A Systematic Review

David F. Lo Rowan University

Hasan Zia

Rutgers University - New Brunswick/Piscataway

Adarsh Thakur

Rutgers University - New Brunswick/Piscataway

Praneetha Rajkumar

Rutgers University - New Brunswick/Piscataway

Don D. Shamilov

Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

Part of the Health and Medical Administration Commons, Investigative Techniques Commons, Other Chemicals and Drugs Commons, Patient Safety Commons, Psychiatric and Mental Health Commons, and the Psychiatry Commons

Let us know how access to this document benefits you - share your thoughts on our feedback form.

Lo, David F.; Zia, Hasan; Thakur, Adarsh; Rajkumar, Praneetha; and Shamilov, Don D., "The Effects of Psychedelic Microdosing on Mental Health: A Systematic Review" (2024). *Rowan-Virtua Research Day*. 96.

https://rdw.rowan.edu/stratford_research_day/2024/may2/96

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.



The Effects of Psychedelic Microdosing on Mental Health: A Systematic Review

David F. Lo, Hasan Zia, Adarsh Thakur, Pranetha Rajkumar, Don D. Shamilov


Abstract

- Psychedelic microdosing is taking small doses of substances such as LSD or psilocybin
- Studies have explored the impact of microdosing on mental health conditions
- Those facing mental health challenges have turned to psychedelic microdosing to improve their mental health
- Benefits and drawbacks of microdosing explored

Introduction

- Mental health is a growing concern around the country
- The United States has roughly 5.5 million users of psychedelics
- The most common drugs include LSD and psilocybin but others such as mescaline, DMT, and amphetamines are also used
- Despite growing popularity, there are limited studies on the effects of psychedelic microdosing on mental health

Study Distribution




Methodology

- 42 articles (24 from PubMed and 18 from Scopus) observed
- After screening for duplicates and relevancy, 16 articles were included for the final review
- Overall key terms were based on concepts such as "psychedelics," "microdosing," and "mental health"
- Different types of research articles such as observational, placebo, self-reported, motivational, and comparative studies, as well as one literature review were included
- English written and translated papers were included
- No limitations placed on types of studies

Results

- According to one study, those who microdosed demonstrated lower levels of anxiety, depression, and stress compared to those who did not microdose
- The primary motivations for microdosing was to improve mental health, personal development and cognitive enhancement
- Benefits included increased productivity, mood, and concentration as well as decreased levels of anxiety
- An overall improvement in the well being of those who microdosed was observed
- Drawbacks of microdosing included difficulty sleeping and headaches



Discussion

- Microdosing noted to treat mental health issues among new and experienced microdosers as well as cancer patients
- Despite some limitations being noted when observing the conclusions of the studies done, a correlation between improved mental health and psychedelics was established

Conclusion

- Psychedelic microdosing for mental health is still a novel topic
- Further research that understands the relationship between the two would aid in achieving a greater understanding in the role of this modality for treating mental health concerns
- Future studies that include larger sample sizes as well as double blind studies will contribute to a better understanding of the topic

Acknowledgements

 The authors would like to acknowledge Dr. Aayush Visaria for their guidance on this paper